Skip to main content
. 2020 Feb 26;25(5):1039. doi: 10.3390/molecules25051039

Figure 3.

Figure 3

Impact of heparin derivatives on platelet aggregation and secretion after platelet shape change. (A) Platelets were stimulated with TRAP-6, MDA-MB-231, or MCF-7 cells, respectively, and P-selectin expression was determined by flow cytometry; (B) representative traces showing platelet-tumor cell aggregation in response to PAR-1 receptor agonist TRAP-6 (41 µM or 10 µM, respectively). Platelets were preincubated for 30 min with 100 µg/mL P-selectin inhibitor (n = 5); (C) representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231 or MCF-7 cells, respectively. P-selectin inhibitor (100 µg/mL) was added 5 min (10 min in case of MCF-7 cells) after tumor cell addition when platelet shape change was in progress (n = 5); (D–F) representative traces showing platelet-tumor cell aggregation in response to MDA-MB-231, or MCF-7 cells, respectively, when RO-heparin (100 µg/mL) (D), 2-O-desulfated heparin (100 µg/mL) (E), or fondaparinux (775 ng/mL) (F) were added 5 min/10 min after tumor cell addition when platelet shape change was in progress (n = 5).